Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis, a potentially lethal disease often underdiagnosed on the African continent.
With this first shipment to Djibouti, Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines, vaccines and healthcare for underserved populations.
Sanofi's social model to broaden access is channeled through its Global Health Unit (GHU). The first global initiative of its kind, Sanofi’s GHU aims to provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs.
To that point, the GHU created Impact, a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi, some of which are considered to be "essential" by the World Health Organization (WHO).
The Impact medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.
Jon Fairest, Head, Global Health Unit, Sanofi, said: "I'm delighted to see the very first Impact brand medicine, Enoxaparin Sodium Impact, arrive on Djibouti soil. This is an important milestone in Sanofi’s long-term objective to reach 2 million people with noncommunicable diseases in underserved populations by 2030."
"But providing access to quality medicines and sustainable healthcare to people in the 40 most underserved countries is not a simple task. It requires cross-sector partnerships on a global, regional, and importantly, on a local scale – work Sanofi does on the ground with the GHU teams."
"After Djibouti, we are now heading to Tanzania, scheduled to be the second country to receive an Impact brand medicine: Insulin Glargine Impact.”
